<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="into the human population. While the occurrence of a future" exact="influenza" post="pandemic is almost certain, it is impossible to predict"/>
 <result pre="in 2009 but caused relatively mild symptoms and the 1918" exact="influenza" post="A H1N1 pandemic (&quot;Spanish flu&quot;) on the other hand,"/>
 <result pre="of around 50 million people ( 1). Currently licensed seasonal" exact="influenza" post="vaccines are specific for pre-defined viral strains and are"/>
 <result pre="Hence, new vaccine technologies able to induce broad protection against" exact="influenza" post="A viruses are urgently required. Severe acute respiratory syndrome"/>
 <result pre="in the last decades: according to the WHO, cases of" exact="dengue fever" post="have risen 30-fold in the past 50 years. Zika"/>
 <result pre="of Zika in South America, with over 4,000 cases of" exact="microcephaly" post="led to the declaration of a Public Health Emergency"/>
 <result pre="MDR organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant" exact="tuberculosis" post="(MDR-TB) are becoming a serious threat to global public"/>
 <result pre="for SARS and MERS CoV. The outbreaks caused by pandemic" exact="influenza" post="virus demonstrate the potential of a known pathogen to"/>
 <result pre="known and vaccine manufacturing technologies are established, like for pandemic" exact="influenza" post="vaccine, production capacity to meet peak demands during a"/>
 <result pre="coordinated by the WHO, the potential production capacity for pandemic" exact="influenza" post="vaccines in 2015 could in theory support the vaccination"/>
 <result pre="according to a survey made in 2015, only 5% of" exact="influenza" post="vaccine doses were distributed among Southeast Asia, Eastern Mediterranean,"/>
 <result pre="vaccines would take 5–3 months between identification of a pandemic" exact="influenza" post="and vaccine distribution, which would give a pandemic virus"/>
 <result pre="or 26; ChAd, chimpanzee adenovirus; HIV, human immunodeficiency virus; H5N1," exact="influenza" post="H5N1; H1N1 pdm09, influenza H1N1 2009 &quot;swine flu&quot;; H10N8,"/>
 <result pre="adenovirus; HIV, human immunodeficiency virus; H5N1, influenza H5N1; H1N1 pdm09," exact="influenza" post="H1N1 2009 &quot;swine flu&quot;; H10N8, influenza H10N8; DNA, deoxyribonucleic"/>
 <result pre="influenza H5N1; H1N1 pdm09, influenza H1N1 2009 &quot;swine flu&quot;; H10N8," exact="influenza" post="H10N8; DNA, deoxyribonucleic acid based vaccine, MVA, modified vaccinia"/>
 <result pre="modified vaccinia Ankara; RNA, ribonucleic acid based vaccine; VSV, vesicular" exact="stomatitis" post="virus; HPIV3, human parainfluenza virus type 3; MV, measles"/>
 <result pre="vesicular stomatitis virus; HPIV3, human parainfluenza virus type 3; MV," exact="measles" post="virus. Viral vector based vaccines Viral vector based vaccines,"/>
 <result pre="adeno-associated viruses, AAV), togaviruses (e.g., Semliki Forest virus), paramyxoviruses (e.g.," exact="measles" post="virus, Newcastle disease virus or human parainfluenza virus), rhabdoviruses"/>
 <result pre="Newcastle disease virus or human parainfluenza virus), rhabdoviruses (e.g., vesicular" exact="stomatitis" post="virus, VSV), and poxviruses (e.g., Modified vaccinia Ankara, MVA)."/>
 <result pre="will only describe some commonly used viral vectors, i.e., adenovirus," exact="measles" post="virus, and VSV in some detail, whose use in"/>
 <result pre="restrict availability of manufacturing facilities in an outbreak setting. Recombinant" exact="measles" post="viruses are able to induce high levels of both"/>
 <result pre="Dengvaxia, which is a recombinant Dengue vaccine based on the" exact="yellow fever" post="attenuated strain 17D, has been licensed for human use."/>
 <result pre="parainfluenza virus type 3 (HPIV3), recombinant cytomegalovirus (rCMV), and recombinant" exact="rabies" post="virus (RABV). Clinical trials were conducted for VSV-EBOV, ChAd3"/>
 <result pre="GP EBOV (1995) Safety: Mild adverse events, no cases of" exact="arthritis" post="Immunogenicity: - Antibody titers in all participants by day"/>
 <result pre="higher: - Arthralgia in 22% (11/51) participants of Geneva cohort;" exact="arthritis" post="confirmed in 9/ 11 cases; maculopapular rash in 27%"/>
 <result pre="of Geneva cohort; arthritis confirmed in 9/ 11 cases; maculopapular" exact="rash" post="in 27% (3/11) of these cases - Self-limiting cases"/>
 <result pre="in 27% (3/11) of these cases - Self-limiting cases of" exact="arthritis" post="in 3.4% (2/60) participants in Germany and Kenya cohort"/>
 <result pre="Unit; SUDV, Sudan virus; VNT, virus neutralization titers; VSV, vesicular" exact="stomatitis" post="virus; VP, viral particles. * Boost with MVA based"/>
 <result pre="10 7 PFU or higher were associated with the development" exact="arthritis" post="lasting a median of 8 days. In addition, some"/>
 <result pre="days. In addition, some participants experiencing arthralgia developed a maculopapular" exact="rash" post="indicative of VSV replication and dissemination. Following this, the"/>
 <result pre="participants but only mild adverse events without further cases of" exact="arthritis" post="( 73). A phase II/III clinical trial (NCT02378753) was"/>
 <result pre="against a large variety of human pathogens such as HIV," exact="influenza" post="virus, malaria, hepatitis B virus, respiratory syncytial and herpes"/>
 <result pre="variety of human pathogens such as HIV, influenza virus, malaria," exact="hepatitis" post="B virus, respiratory syncytial and herpes simplex virus. No"/>
 <result pre="HIV, influenza virus, malaria, hepatitis B virus, respiratory syncytial and" exact="herpes simplex" post="virus. No DNA based vaccine is licensed for human"/>
 <result pre="inhibition; ID, intradermal; IL-12, interleukin 12; IM, intramuscular; JEV, Japanese" exact="encephalitis" post="virus; M2, ion channel protein influenza; MARV, Marburg virus;"/>
 <result pre="assessed the ability of DNA vaccines to mediated protection against" exact="influenza" post="viruses, either alone or as part of prime boost"/>
 <result pre="tested a vaccine that targets the highly pathogenic avian H5N1" exact="influenza" post="endemic in poultry. Its ability to cross the species"/>
 <result pre="and trivalent groups, respectively. Upon emergence of a novel H1N1" exact="influenza" post="that originated in pigs and became pandemic in humans"/>
 <result pre="whose GMP production was finalized 2 months before licensed monovalent" exact="influenza" post="vaccines became available ( 101) (Table 2). However, 4"/>
 <result pre="to 72%, 4 weeks after boosting with a licensed monovalent" exact="influenza" post="vaccine. Based on results gained at this point, the"/>
 <result pre="support the use of DNA-based vaccines for controlling a potential" exact="influenza" post="pandemic by employing DNA as an initial priming agent,"/>
 <result pre="as an initial priming agent, followed by boosting with conventional" exact="influenza" post="vaccines upon availability. DNA based vaccines were among the"/>
 <result pre="regions (VRC5288) were exchanged with the corresponding sequences from Japanese" exact="encephalitis" post="virus (JEV). Both vaccine candidates are evaluated in clinical"/>
 <result pre="(ARCA) in the reaction ( 115), or subsequently, using the" exact="vaccinia virus" post="capping complex ( 116). The UTRs, which can be"/>
 <result pre="and capable of inducting protection against lethal challenge infections with" exact="influenza" post="or rabies virus in several animal models ( 124,"/>
 <result pre="of inducting protection against lethal challenge infections with influenza or" exact="rabies" post="virus in several animal models ( 124, 151). Using"/>
 <result pre="nucleoside-modified mRNA-LNP vaccines against the Zika virus, as well as" exact="influenza" post="A H10N8 and H7N9 viruses proved to be immunogenic"/>
 <result pre="163). Single IM immunization of NHPs with LNP-formulated mRNAs encoding" exact="rabies" post="or influenza antigens induced protective antibody titers, which could"/>
 <result pre="IM immunization of NHPs with LNP-formulated mRNAs encoding rabies or" exact="influenza" post="antigens induced protective antibody titers, which could be boosted"/>
 <result pre="to antibody responses elicited by a modified non-replicating mRNA encoding" exact="influenza" post="A H10 HA encapsulated in LNPs showed that, while"/>
 <result pre="ID delivery generated this response more rapidly ( 168). Circulating" exact="influenza" post="H10-specific memory B cells expanded after each of the"/>
 <result pre="shown to correlate with high avidity antibody responses after seasonal" exact="influenza" post="vaccination in humans. In addition, a non-replicating sequence optimized"/>
 <result pre="mRNA vaccine induced long-lived functional antibody responses against HA of" exact="influenza" post="A H1N1pdm in NHPs which persisted for one year"/>
 <result pre="potential ( 162, 173– 176). Self-amplifying mRNA vaccines encoding various" exact="influenza" post="antigens complexed with LNP or oil-in-water cationic nanoemulsions (CNE)"/>
 <result pre="containment of viral replication in the upper respiratory tract upon" exact="influenza" post="infection and conferred protection against homologous and heterosubtypic viral"/>
 <result pre="nanoparticle (MDNP)-based RNA replicon vaccine platform provides protection against lethal" exact="influenza" post="and Ebola virus infections and elicits antibody and CD8"/>
 <result pre="that ID administration of protamine-complexed non-replicating sequence-optimized mRNA vaccines encoding" exact="influenza" post="HA was protective in mice upon homologous challenge with"/>
 <result pre="influenza HA was protective in mice upon homologous challenge with" exact="influenza" post="H1N1, H3N2, and H5N1 and was immunogenic in ferrets"/>
 <result pre="nucleotides, that encoded for HA proteins of the potentially pandemic" exact="influenza" post="A subtypes H10N8 or H7N9 ( 159). A single"/>
 <result pre="vaccines for human use and clinical trials testing vaccines against" exact="influenza" post="and Zika have furthermore highlighted the speed of vaccine"/>
 <result pre=". Updating the accounts: global mortality of the 1918-1920 &quot;Spanish&quot;" exact="influenza" post="pandemic. Bull Hist Med. ( 2002) 76: 105– 15."/>
 <result pre="al. . Identification of a novel coronavirus in patients with" exact="severe acute respiratory syndrome." post="N Engl J Med. ( 2003) 348: 1967– 76."/>
 <result pre="Peiris JS Yuen KY Osterhaus AD Stohr K . The" exact="severe acute respiratory syndrome." post="N Engl J Med. ( 2003) 349: 2431– 41."/>
 <result pre="from a Phase 3 clinical trial of a live-attenuated chimeric" exact="yellow fever" post="tetravalent dengue vaccine . Hum Vaccin Immunother. ( 2018)"/>
 <result pre=". The 2015 global production capacity of seasonal and pandemic" exact="influenza" post="vaccine. Vaccine ( 2016) 34: 5410– 3. 10.1016/j.vaccine.2016.08.019 27531411"/>
 <result pre="Toth K . Adenovirus vectors for gene therapy, vaccination and" exact="cancer" post="gene therapy. Curr Gene Ther. ( 2013) 13: 421–"/>
 <result pre="Hangartner L Caballero M Pavlovic J et al. . Attenuated" exact="measles" post="virus as a vaccine vector. Vaccine ( 2007) 25:"/>
 <result pre="N Jacobson RM Vierkant RA Poland GA . Frequency of" exact="measles" post="virus-specific CD4+ and CD8+ T cells in subjects seronegative"/>
 <result pre="CD8+ T cells in subjects seronegative or highly seropositive for" exact="measles" post="vaccine . Clin Diagn Lab Immunol. ( 2003) 10:"/>
 <result pre="6. 10.1128/CDLI.10.3.411-416.2003 12738640 35. Muhlebach MD . Vaccine platform recombinant" exact="measles" post="virus. Virus Genes ( 2017) 53: 733– 40. 10.1007/s11262-017-1486-3"/>
 <result pre="E Tangy F Herman P . Biosafety considerations for attenuated" exact="measles" post="virus vectors used in virotherapy and vaccination . Hum"/>
 <result pre="ND Stillman EA Whitt MA Rose JK . Recombinant vesicular" exact="stomatitis" post="viruses from DNA. Proc Natl Acad Sci USA. ("/>
 <result pre="Den Pol AN Davis JN . Highly attenuated recombinant vesicular" exact="stomatitis" post="virus VSV-12'GFP displays immunogenic and oncolytic activity . J"/>
 <result pre="Draper K et al. . Neurovirulence properties of recombinant vesicular" exact="stomatitis" post="virus vectors in non-human primates . Virology ( 2007)"/>
 <result pre="et al. . Live virus vaccines based on a vesicular" exact="stomatitis" post="virus (VSV) backbone: standardized template with key considerations for"/>
 <result pre="Garg SJ Tucker SN . High titre neutralising antibodies to" exact="influenza" post="after oral tablet immunisation: a phase 1, randomised, placebo-controlled"/>
 <result pre=". Oral administration of an adenovirus vector encoding both an" exact="avian influenza" post="A hemagglutinin and a TLR3 ligand induces antigen specific"/>
 <result pre="Oral administration of an adenovirus vector encoding both an avian" exact="influenza" post="A hemagglutinin and a TLR3 ligand induces antigen specific"/>
 <result pre=". Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored" exact="malaria" post="vaccines adjuvanted with Matrix-M . Vaccine ( 2017) 35:"/>
 <result pre="P Wagner R et al. . Properties of replication-competent vesicular" exact="stomatitis" post="virus vectors expressing glycoproteins of filoviruses and arenaviruses ."/>
 <result pre="Martellaro C Kobinger G Feldmann H . Efficacy of vesicular" exact="stomatitis" post="virus-Ebola virus postexposure treatment in Rhesus Macaques infected With"/>
 <result pre="Castellano AR Hu Z et al. . A recombinant vesicular" exact="stomatitis" post="virus Ebola vaccine. N Engl J Med. ( 2017)"/>
 <result pre="Rusalov D Geall A Enas J et al. . Vaxfectin-formulated" exact="influenza" post="DNA vaccines encoding NP and M2 viral proteins protect"/>
 <result pre="protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1)" exact="influenza" post="virus . J Infect Dis. ( 2008) 197: 1643–"/>
 <result pre="Lindstrom S et al. . Emergence of a novel swine-origin" exact="influenza" post="A (H1N1) virus in humans. N Engl J Med."/>
 <result pre="of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-)methyltransferase complex from" exact="vaccinia virus." post="J Biol Chem. ( 1980) 255, 903– 908. 6243301"/>
 <result pre="Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infection . Nat Biotechnol. ( 2012) 30:"/>
 <result pre="et al. . An alphavirus replicon particle chimera derived from" exact="venezuelan equine encephalitis" post="and sindbis viruses is a potent gene-based vaccine delivery"/>
 <result pre=". An alphavirus replicon particle chimera derived from venezuelan equine" exact="encephalitis" post="and sindbis viruses is a potent gene-based vaccine delivery"/>
 <result pre="et al. . Self-amplifying RNA vaccines give equivalent protection against" exact="influenza" post="to mRNA vaccines but at much lower doses ."/>
 <result pre=". Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against" exact="cancer" post=". Nature ( 2017) 547: 222– 6. 10.1038/nature23003 28678784"/>
 <result pre="immune response to RNA immunization with flavivirus replicons derived from" exact="tick-borne encephalitis" post="virus . J Virol ( 2005) 79: 15107– 13."/>
 <result pre="response to RNA immunization with flavivirus replicons derived from tick-borne" exact="encephalitis" post="virus . J Virol ( 2005) 79: 15107– 13."/>
 <result pre="A Duchardt KM et al. . Highly potent mRNA based" exact="cancer" post="vaccines represent an attractive platform for combination therapies supporting"/>
 <result pre="P Kramps T et al. . An mRNA vaccine encoding" exact="rabies" post="virus glycoprotein induces protection against lethal infection in mice"/>
 <result pre="G et al. . Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
 <result pre="demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9" exact="influenza" post="viruses . Mol Ther. ( 2017) 25: 1316– 27."/>
 <result pre="et al. . Induction of robust B cell responses after" exact="influenza" post="mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+"/>
 <result pre="broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding" exact="influenza" post="virus hemagglutinin . J Virol. ( 2016) 90: 332–"/>
 <result pre="JB et al. . Self-amplifying mRNA vaccines expressing multiple conserved" exact="influenza" post="antigens confer protection against homologous and heterosubtypic viral challenge"/>
 <result pre="et al. . Rapidly produced SAM ® vaccine against H7N9" exact="influenza" post="is immunogenic in mice . Emerg Microbes Infect. ("/>
</results>
